FDA approves new treatment Galafold (migalastat) for a rare genetic disorder, Fabry disease

New Drug Approvals

FDA approves new treatment for a rare genetic disorder, Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation determined to be responsive (“amenable”) to treatment with Galafold based on laboratory data. Fabry disease is a rare and serious genetic disease that results from buildup of a type of fat called globotriaosylceramide (GL-3) in blood vessels, the kidneys, the heart, the nerves and other organs.

Continue reading…

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM616598.htm?utm_campaign=08102018_PR_FDA%20approves%20new%20treatment%20for%20a%20rare%20disorder%2C%20Fabry%20disease&utm_medium=email&utm_source=Eloqua

August 10, 2018

Release

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation determined to be responsive (“amenable”) to treatment with Galafold based on laboratory data. Fabry…

View original post 441 more words